scholarly journals Safety profile and effectiveness of alectinib in the real-world surveillance study of 1251 Japanese patients with ALK-positive non-small cell lung cancer

2018 ◽  
Vol 29 ◽  
pp. viii502
Author(s):  
Y. Ohe ◽  
N. Yamamoto ◽  
A. Gemma ◽  
M. Kusumoto ◽  
I. Yamada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Safety Profile ◽  
Japanese Patients ◽  
Small Cell ◽  
Surveillance Study ◽  
Small Cell Lung ◽  
Alk Positive

scholarly journals Safety and effectiveness of alectinib in a real‐world surveillance study in patients with ALK ‐positive non–small‐cell lung cancer in Japan

2019 ◽  
Vol 110 (4) ◽  
pp. 1401-1407 ◽  
Author(s):  
Noriyuki Masuda ◽  
Yuichiro Ohe ◽  
Akihiko Gemma ◽  
Masahiko Kusumoto ◽  
Ikuyo Yamada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Surveillance Study ◽  
Small Cell Lung ◽  
Alk Positive

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)

Lung Cancer ◽  
2019 ◽  
Vol 136 ◽  
pp. 109-114 ◽  
Author(s):  
Renaud Descourt ◽  
Maurice Perol ◽  
Gaëlle Rousseau-Bussac ◽  
David Planchard ◽  
Bertrand Mennecier ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Inhibitors ◽  
Alk Positive

scholarly journals Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib

2019 ◽  
Vol 24 (8) ◽  
pp. 917-926 ◽  
Author(s):  
Kazuo Tamura ◽  
Toshihiro Nukiwa ◽  
Akihiko Gemma ◽  
Nobuyuki Yamamoto ◽  
Masaya Mizushima ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Egfr Mutation ◽  
Japanese Patients ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non‐small‐cell lung cancer

2014 ◽  
Vol 105 (12) ◽  
pp. 1584-1590 ◽  
Author(s):  
Akihiko Gemma ◽  
Shoji Kudoh ◽  
Masahiko Ando ◽  
Yuichiro Ohe ◽  
Kazuhiko Nakagawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Japanese Patients ◽  
Small Cell ◽  
Surveillance Study ◽  
Small Cell Lung ◽  
Safety And Efficacy

scholarly journals Correction to: Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib

2019 ◽  
Vol 24 (9) ◽  
pp. 1169-1169
Author(s):  
Kazuo Tamura ◽  
Toshihiro Nukiwa ◽  
Akihiko Gemma ◽  
Nobuyuki Yamamoto ◽  
Masaya Mizushima ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Egfr Mutation ◽  
Japanese Patients ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program

2020 ◽  
Vol 16 (15) ◽  
pp. 1031-1041 ◽  
Author(s):  
Huamao M Lin ◽  
Xiaoyun Pan ◽  
Peijie Hou ◽  
Susan Allen ◽  
Pia Baumann ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Next Generation ◽  
Small Cell Lung ◽  
Early Access ◽  
Alk Positive ◽  
Access Program

Aim: To assess time-to-treatment discontinuation (TTD) of brigatinib following treatment with ALK tyrosine kinase inhibitor(s) (TKIs) in patients with ALK-positive (ALK+) non-small-cell lung cancer (NSCLC) receiving brigatinib through the international early access program. Patients & analysis: Analysis was performed for patients with ALK+ NSCLC treated with prior ALK TKIs, including next-generation ALK TKIs. Results: Data for 604 patients (21 countries), including patients with prior next-generation ALK TKIs, were reported. The median TTD of brigatinib in patients with prior crizotinib, alectinib, ceritinib or lorlatinib was 10.0, 8.7, 10.3 and 7.5 months, respectively. Conclusion: Brigatinib appears to be effective and tolerable in real-world clinical practice regardless of prior treatment with first or NG ALK TKIs.

Sign in / Sign up

Export Citation Format

Share Document